• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

89锆标记的利妥昔单抗PET-CT在眼眶炎性疾病中的应用

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease.

作者信息

Laban Kamil G, Kalmann Rachel, Leguit Roos J, de Keizer Bart

机构信息

Department of Ophthalmology, University Medical Center Utrecht, Utrecht University, Room E 03.136, P.O. Box 85500, 3508, GA, Utrecht, The Netherlands.

Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.

出版信息

EJNMMI Res. 2019 Jul 30;9(1):69. doi: 10.1186/s13550-019-0530-9.

DOI:10.1186/s13550-019-0530-9
PMID:31363937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6667535/
Abstract

BACKGROUND

Orbital inflammatory diseases are a heterogenic group of conditions that often entail a difficult diagnostic process and many patients are treatment resistant. Inflammatory diseases can be visualized by Zirconium-89-labelled rituximab PET-CT (Zr-rituximab PET/CT). In this study, we describe our experience and possible potential of the Zr-rituximab PET/CT for diagnostic and therapeutic management of refractory orbital inflammation.

RESULTS

Retrospectively, Zr-rituximab uptake was assessed and related to clinical data. The main outcome measures were the characteristics of the scan and the clinical relation of uptake with the diagnostic process and treatment effectivity. Twelve patients with thyroid eye disease (TED) and suspected idiopathic orbital inflammation (IOI) were scanned. Six patients had a strong Zr-rituximab uptake and showed a focal distribution within the lesion. Four patients (one TED, three IOI) responded well to rituximab treatment after a positive scan. Zr-rituximab PET/CT was essential to the diagnosis of optic nerve meningioma in one patient.

CONCLUSION

Zr-rituximab PET/CT has the potential to be a powerful tool for the detection of B cell-mediated disease within the orbit and ocular adnexa. This technique can be a valuable addition for diagnosing diseases around the eye and can potentially predict rituximab treatment response in patients with refractory inflammation.

摘要

背景

眼眶炎性疾病是一组异质性疾病，诊断过程往往困难，许多患者对治疗耐药。炎性疾病可通过锆 - 89标记的利妥昔单抗PET - CT（Zr - 利妥昔单抗PET/CT）进行可视化。在本研究中，我们描述了Zr - 利妥昔单抗PET/CT在难治性眼眶炎症的诊断和治疗管理中的经验及潜在价值。

结果

回顾性评估Zr - 利妥昔单抗摄取情况并与临床数据相关联。主要观察指标为扫描特征以及摄取情况与诊断过程和治疗有效性的临床关系。对12例甲状腺眼病（TED）和疑似特发性眼眶炎症（IOI）患者进行了扫描。6例患者Zr - 利妥昔单抗摄取强烈，病变内呈局灶性分布。4例患者（1例TED，3例IOI）扫描阳性后对利妥昔单抗治疗反应良好。Zr - 利妥昔单抗PET/CT对1例视神经脑膜瘤的诊断至关重要。

结论

Zr - 利妥昔单抗PET/CT有潜力成为检测眼眶及眼附属器内B细胞介导疾病的有力工具。该技术可为眼部周围疾病的诊断提供有价值的补充，并有可能预测难治性炎症患者的利妥昔单抗治疗反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b415/6667535/a6b589c87c1b/13550_2019_530_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b415/6667535/6704054369b3/13550_2019_530_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b415/6667535/5f33d5b9feee/13550_2019_530_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b415/6667535/a6b589c87c1b/13550_2019_530_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b415/6667535/6704054369b3/13550_2019_530_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b415/6667535/5f33d5b9feee/13550_2019_530_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b415/6667535/a6b589c87c1b/13550_2019_530_Fig3_HTML.jpg

相似文献

1
Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease.89锆标记的利妥昔单抗PET-CT在眼眶炎性疾病中的应用
EJNMMI Res. 2019 Jul 30;9(1):69. doi: 10.1186/s13550-019-0530-9.
2
[Zr]Zr-rituximab PET/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study.[锆]锆标记利妥昔单抗PET/CT在治疗难治性间质性肺炎患者中的活性：一项可行性研究。
Am J Nucl Med Mol Imaging. 2019 Dec 15;9(6):296-308. eCollection 2019.
3
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
4
Altered splenic [Zr]Zr-rituximab uptake in patients with interstitial lung disease not responding to rituximab: could this indicate a splenic immune-mediated mechanism?利妥昔单抗治疗无效的间质性肺疾病患者脾脏[锆]锆-利妥昔单抗摄取改变：这是否表明存在脾脏免疫介导机制？
Am J Nucl Med Mol Imaging. 2020 Aug 25;10(4):168-177. eCollection 2020.
5
Interobserver reproducibility of tumor uptake quantification with Zr-immuno-PET: a multicenter analysis.Zr 免疫 PET 肿瘤摄取定量的观察者间可重复性：一项多中心分析。
Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1840-1849. doi: 10.1007/s00259-019-04377-6. Epub 2019 Jun 17.
6
Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with Zr in Human Lymphoma Xenografts.评估 Zr 标记的新一代抗 CD20 抗体在人淋巴瘤异种移植模型中的疗效。
J Nucl Med. 2018 Aug;59(8):1219-1224. doi: 10.2967/jnumed.117.203299. Epub 2018 Jan 18.
7
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.用（89）Zr-利妥昔单抗免疫PET预测（90）Y-利妥昔单抗在CD20+B细胞淋巴瘤中的放射免疫治疗的肿瘤靶向性和辐射剂量：未标记利妥昔单抗预负荷的影响
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14. doi: 10.1007/s00259-015-3025-6. Epub 2015 Mar 20.
8
Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.用 89Zr-去铁胺标记的 CD30 特异性 AC-10 抗体进行 CD30 阳性淋巴瘤的免疫 -PET 成像。
J Nucl Med. 2016 Jan;57(1):96-102. doi: 10.2967/jnumed.115.162735. Epub 2015 Oct 29.
9
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.89Zr标记的利妥昔单抗PET作为评估CD20靶向性的成像生物标志物的性能：复发/难治性弥漫性大B细胞淋巴瘤患者的一项初步研究
PLoS One. 2017 Jan 6;12(1):e0169828. doi: 10.1371/journal.pone.0169828. eCollection 2017.
10
Tocilizumab in a Case of Refractory Idiopathic Orbital Inflammation: 6-Year Follow-Up Outcomes.托珠单抗治疗难治性特发性眼眶炎症1例：6年随访结果
Case Rep Ophthalmol. 2020 Jul 6;11(2):299-305. doi: 10.1159/000508237. eCollection 2020 May-Aug.

引用本文的文献

1
Emerging PET radiotracers for vascular imaging.用于血管成像的新型正电子发射断层显像（PET）放射性示踪剂。
Rheumatology (Oxford). 2025 Mar 1;64(Supplement_1):i33-i37. doi: 10.1093/rheumatology/keae635.
2
Advances and challenges in immunoPET methodology.免疫正电子发射断层扫描（immunoPET）方法的进展与挑战
Front Nucl Med. 2024 Feb 19;4:1360710. doi: 10.3389/fnume.2024.1360710. eCollection 2024.
3
Predictive markers for anti-inflammatory treatment response in thyroid eye disease.甲状腺眼病抗炎治疗反应的预测标志物。

本文引用的文献

1
Diffusivity of intraorbital lymphoma vs. inflammation: comparison of single shot turbo spin echo and multishot echo planar imaging techniques.球内淋巴瘤与炎症的扩散率：单次激发 turbo 自旋回波与多次激发回波平面成像技术的比较。
Eur Radiol. 2018 Jan;28(1):325-330. doi: 10.1007/s00330-017-4995-5. Epub 2017 Aug 4.
2
Consensus on Diagnostic Criteria of Idiopathic Orbital Inflammation Using a Modified Delphi Approach.采用改良德尔菲法对特发性眼眶炎症诊断标准的共识
JAMA Ophthalmol. 2017 Jul 1;135(7):769-776. doi: 10.1001/jamaophthalmol.2017.1581.
3
Cerebral rituximab uptake in multiple sclerosis: A Zr-immunoPET pilot study.
Front Endocrinol (Lausanne). 2023 Dec 4;14:1292519. doi: 10.3389/fendo.2023.1292519. eCollection 2023.
4
Current imaging methods for assessing Graves` orbitopathy activity with particular emphasis on FDG-PET.评估格雷夫斯眼病活动的当前成像方法，特别强调 FDG-PET。
Front Endocrinol (Lausanne). 2023 Aug 3;14:1138569. doi: 10.3389/fendo.2023.1138569. eCollection 2023.
5
Rituximab for treatment of non-infectious and non-malignant orbital inflammatory disease.利妥昔单抗用于治疗非感染性非恶性眼眶炎性疾病。
J Ophthalmic Inflamm Infect. 2021 Aug 27;11(1):24. doi: 10.1186/s12348-021-00253-3.
6
Ultrasound and Bioptic Investigation of Patients with Primary Sjögren's Syndrome.原发性干燥综合征患者的超声与活检研究
J Clin Med. 2021 Mar 11;10(6):1171. doi: 10.3390/jcm10061171.
7
Imaging in Primary Sjögren's Syndrome.原发性干燥综合征的影像学检查
J Clin Med. 2020 Aug 3;9(8):2492. doi: 10.3390/jcm9082492.
8
New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy.靶向治疗时代难治性巩膜炎的新潜在武器。
Mediators Inflamm. 2020 Jan 17;2020:8294560. doi: 10.1155/2020/8294560. eCollection 2020.
9
ImmunoPET: Concept, Design, and Applications.免疫正电子发射断层扫描：概念、设计与应用。
Chem Rev. 2020 Apr 22;120(8):3787-3851. doi: 10.1021/acs.chemrev.9b00738. Epub 2020 Mar 23.
10
Zirconium-89 labelled rituximab PET-CT imaging of Graves' orbitopathy.锆-89标记的利妥昔单抗PET-CT对格雷夫斯眼眶病的成像
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):738-739. doi: 10.1007/s00259-019-04599-8. Epub 2019 Nov 18.
多发性硬化症中的大脑利妥昔单抗摄取：Zr 免疫 PET 初步研究。
Mult Scler. 2018 Apr;24(4):543-545. doi: 10.1177/1352458517704507. Epub 2017 Apr 26.
4
Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.89Zr标记的利妥昔单抗PET作为评估CD20靶向性的成像生物标志物的性能：复发/难治性弥漫性大B细胞淋巴瘤患者的一项初步研究
PLoS One. 2017 Jan 6;12(1):e0169828. doi: 10.1371/journal.pone.0169828. eCollection 2017.
5
B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.在类风湿关节炎患者中，基线时使用锆-89标记的利妥昔单抗进行PET-CT的B细胞成像与开始利妥昔单抗治疗24周后的治疗反应相关。
Arthritis Res Ther. 2016 Nov 18;18(1):266. doi: 10.1186/s13075-016-1166-z.
6
MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials.内分泌疾病管理：利妥昔单抗治疗格雷夫斯眼病——来自随机对照试验的经验。
Eur J Endocrinol. 2017 Feb;176(2):R101-R109. doi: 10.1530/EJE-16-0552. Epub 2016 Oct 19.
7
Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?肿瘤学中使用锆-89标记单克隆抗体的免疫正电子发射断层扫描：我们能从初步临床试验中学到什么？
Front Pharmacol. 2016 May 24;7:131. doi: 10.3389/fphar.2016.00131. eCollection 2016.
8
Orbital inflammation: Biopsy first.眼眶炎症：先进行活检。
Surv Ophthalmol. 2016 Sep-Oct;61(5):664-9. doi: 10.1016/j.survophthal.2016.03.002. Epub 2016 Mar 17.
9
Orbital inflammation: Corticosteroids first.眼眶炎症：首先使用皮质类固醇。
Surv Ophthalmol. 2016 Sep-Oct;61(5):670-3. doi: 10.1016/j.survophthal.2016.01.005. Epub 2016 Mar 10.
10
(89) Zr-rituximab PET/CT to detect neurolymphomatosis.用于检测神经淋巴瘤病的（89）锆-利妥昔单抗正电子发射断层扫描/计算机断层扫描（PET/CT）
Am J Hematol. 2016 Jun;91(6):649-50. doi: 10.1002/ajh.24328. Epub 2016 Apr 13.